Versiti continues to innovate and add to our test menu, helping physicians offer patients superior treatment options.
Versiti offers all the companion diagnostic tests that can aid in identifying acute myeloid leukemia (AML) patients at diagnosis and/or relapse. Patients with IDH1 and IDH2 mutations may be treated with the FDA-approved drugs ivosidenib (TIBSOVO®) and enasidenib (IDHIFA®). Patients with FLT3 mutations may be treated with FDA-approved drugs midostaurin (RYDAPT®) and gilteritinib (XOSPATA®).
The value of molecular oncology testing from Versiti
- Don’t wait for precision laboratory medicine. Since the launch of both IDH assays in August 2018, Versiti has rapidly reported test results within an average of four days.
- Identify more patients who could benefit from new targeted therapies. IDH Abbott tests have high detection rates, down to 1% mutational burden as documented in FDA submissions.
- The LeukoStrat FLT3 test is the only internationally standardized quantitative test for both ITD and TKD mutations.
NEW! LeukoStrat CDx FLT3 Mutation Assay (Test Code: 4675)
This new test is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an FLT3 mutation for treatment with FDA-approved drugs midostaurin (RYDAPT®) and gilteritinib (XOSPATA®). Learn more.
NEW! IDH1 Abbott Realtime PCR test (Test Code: 7647)
This new test is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-1 (IDH1) mutation for treatment with TIBSOVO® (ivosidenib). Learn More.
NEW! IDH2 Abbott Realtime PCR test (Test Code: 7648)
This new test is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-2 (IDH2) mutation for treatment with IDHIFA® (enasidenib). Learn More.